PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) will announce results for the first quarter of 2025 on Thursday, April 24, 2025. Company executives will review financial results ...

Approval of the bluebird bio-partnered CAR-T is one part of a three-part, all-or-nothing wager between BMS and former shareholders in Celgene, which it acquired in a mega-merger last year.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), today announced a definitive merger agreement under which Bristol Myers Squibb (NYSE: BMY) (“BMS”) will acquire all of the ...